| 試験No | 投稿誌 | リファレンス | 論文名 | 執筆者 |
| 2021年度（2021/4～2021/9） | ||||
| 1607 | JTO Clinical and Research Reports | https://doi.org/ 10.1016/j.jtocrr. 2021.100191 |
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib | 大分大学 小副川 敦 |
| 0902 | ESMO Open | https://doi.org/ 10.1016/j.esmoop. 2021.100191 |
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study | 岡山大学 堀田 勝幸 |
| 2020年度（2020/4～2021/3） | ||||
| 1101 | The Oncologist | 2020;25:1-10 | Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study | 九州がんセンター 野崎 要 |
| 0602 | BMC Cancer | 2020 4; 20(1):1192 | A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study | 長崎大学 土屋 智史 |
| 1603 | BMC Cancer (プロトコール論文) |
2020 1;20(1):370 | A Phase II Study of Osimertinib for Patients with Radiotherapy-naive CNS Metastasis of Non-Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the OCEAN Study (LOGIK 1603/WJOG 9116L) | 長崎大学 福田 実 |
| 1604 | Eur J Cancer. | 2021;149:14-22 | Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial | 九州大学 田中 謙太郎 |
| 2019年度（2019/4～2020/3） | ||||
| 0403 | The Oncologist | doi 10,1634/ 2019-0513t |
Randomized, phase II study of weekly paclitaxel plus carboplatin versus biweekly paclitaxel plus carboplatin for patients with previously untreated advanced non-small cell lung cancer | 京都府立医科大学 病院 高山 浩一 |
| 0406 | The Oncologist | doi 10,1634/ 2019-0717 |
Phase II study on biweekly combination therapy of gemcitabine plus carboplatin for the treatment of elderly patients with advanced non-small cell lung cancer | 京都府立医科大学 病院 高山 浩一 |
| 0408 | Journal of Clinical Medicin |
2019,8,2196; doi：10.3390/ jcm8122196. |
Phase Ⅰ/II study of docetaxel and S-1 in previously-treated patients with advanced non-small cell lung cancer:LOGIK0408 | 京都府立医科大学 病院 高山 浩一 |
| 1401-B | The Oncologist | 2019;24:1-9 | Survival analysis for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance ststus treated with alectinib:Updated results of Lung Oncology Group in Kyushu1401 | 九州大学 岩間 映二 |
| 1605 | Thoracic Cancer (プロトコール論文) |
11-2019- 3421.R1 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma:study protocol of LOGIK1605/Tart-1501 | 長崎大学 福田 実 |
| 2018年度（2018/4～2019/3） | ||||
| 1201 | Lung Cancer | 132(2019)1-8 | Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lu ng cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201) | 長崎大学 福田 実 |
| 2017年度（2017/4～2018/3） | ||||
| 1401 | J Thorac Oncol | 2017 12(7): 1161-1166 | Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401) | 九州大学 岩間 映二 |